iX Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- iX Biopharma's estimated annual revenue is currently $3M per year.
- iX Biopharma's estimated revenue per employee is $201,000
Employee Data
- iX Biopharma has 15 Employees.
- iX Biopharma grew their employee count by 15% last year.
iX Biopharma's People
| Name | Title | Email/Phone |
|---|
iX Biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 22 | N/A | N/A | N/A |
#2 | $10.7M | 53 | 6% | N/A | N/A |
#3 | $3M | 15 | 15% | N/A | N/A |
#4 | $12.9M | 64 | 5% | N/A | N/A |
#5 | $1330M | 6617 | 7% | N/A | N/A |
What Is iX Biopharma?
iX Biopharma is a listed, specialty pharmaceutical and nutraceutical company focusing on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery. iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer. The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products. Subsidiaries: iX Syrinx ( https://www.ixsyrinx.com ) Entity health ( https://www.entity-health.com )
keywords:N/A
N/A
Total Funding
15
Number of Employees
$3M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Singapore
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 15 | 7% | N/A |
#2 | $0.4M | 15 | -68% | $16M |
#3 | $1.3M | 15 | 0% | N/A |
#4 | $0.9M | 15 | -6% | N/A |
#5 | $1.3M | 15 | -21% | N/A |